Window-to-China

Overview of last view News

Team from Shanghai Jiaotong University breeds grapevines for Southern China

The team around Professor Shiping WANG has optimized grapevines for over 20 years, looking for plants growing in rainy areas, at high groundwater levels and at low light conditions. By using a “root restriction” technology and shelters shed with bamboo slices, 33 promising new varieties were developed.

China Bio news release, January 14, 2013

China Human Proteome Project leads global proteome developments: Fuchu HE

Academician Fuchu HE, President of the Academy of Military Medical Sciences, announces that, by 2014, the China Human Proteome Project will have covered all major diseases. By 2015, China will have put into operation the Phoenix project, by far the largest Chinese investment in the life sciences, which provides a national infrastructure for proteome research at leading universities and academy institutes.

China Bio news release, January 13, 2014

Chinese specialists acknowledge that China’s air pollution is number 4 risk factor for public health

In an article published in Lancet on Dec. 13, 2013, high-rank officials acknowledge that China’s air pollution is a major risk factor for public health including lung cancer and point on the 5 years’ plan on “National Ambient Air Quality Standards” with investments of 277.5 billion USD to reduce air pollution, among other features, to PM2.5 (see “Window-to-China” September 2013).

China Bio news release, January 8, 2014

CITIC Technology Center Shanghai is recognized as a National Enterprise Technology Center

The mother company, CITIC Medical and Health Group, is the largest antibody drug development and manufacturing enterprise directed towards cancer, transplantation and autoimmune diseases. The nomination by the National Development and Reform Commission implies the company to function as a leader for innovative antibody drugs.

China Bio news release, January 7, 2014

Grandhope Biotech: a strong portfolio in regenerative medicine

The Guangdong-based company specializes in medical implants and regenerative biofilms for orthpedica materials, bone filling materials, artificial esophagus, ligaments, spinal membrane pateches etc. Under a license with Orthocell, an Australian startup, the company has introduced ACI (autologous chondrocyte implantation) technology. It cooperates closely with hospitals in the Guangdong area.

China Industrial Biotechnology Network, January 2, 2014